Raloxifene Protects Cisplatin-Induced Renal Injury in Mice via Inhibiting Oxidative Stress

References

• Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925. doi:10.1016/j.bioorg.2019.102925
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Drug Dictionary: cisplatin; 2021. Available from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cisplatin. Accessed August 8, 2021.
   Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740(1):364–378. doi:10.1016/j.ejphar.2014.07.025
   PubMedGoogle Scholar
• McSweeney KR, Gadanec LK, Qaradakhi T, et al. Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers. 2021;13(7):1572. doi:10.3390/cancers13071572
   PubMed Web of Science ®Google Scholar
• Cocetta V, Ragazzi E, Montopoli M. Mitochondrial involvement in cisplatin resistance. Int J Mol Sci. 2019;20(14):3384. doi:10.3390/ijms20143384
   PubMed Web of Science ®Google Scholar
• Goldstein SR. Selective estrogen receptor modulators and bone health. Climacteric. 2021. doi:10.1080/13697137.2021.1936485
   Web of Science ®Google Scholar
• DeMichele A, Troxel AB, Berlin JA, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol. 2008;26(25):4151–4159. doi:10.1200/JCO.2007.14.0921
   PubMed Web of Science ®Google Scholar
• Osmanova S, Sezer E, Turan V, et al. The effects of raloxifene treatment on oxidative status in brain tissues and learning process of ovariectomized rats. Iran J Reprod Med. 2011;9(4):295–300.
   PubMedGoogle Scholar
• Yazğan B, Yazğan Y, Övey İS, et al. Raloxifene and tamoxifen reduce PARP activity, cytokine and oxidative stress levels in the brain and blood of ovariectomized rats. J Mol Neurosci. 2016;60(2):214–222. doi:10.1007/s12031-016-0785-9
   PubMed Web of Science ®Google Scholar
• Vesga-Jiménez DJ, Hidalgo-Lanussa O, Baez-Jurado E, et al. Raloxifene attenuates oxidative stress and preserves mitochondrial function in astrocytic cells upon glucose deprivation. J Cell Physiol. 2019;234(3):2051–2057. doi:10.1002/jcp.27481
   PubMed Web of Science ®Google Scholar
• Wassmann S, Laufs U, Stamenkovic D, et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation. 2002;105(17):2083–2091. doi:10.1161/01.CIR.0000014618.91633.67
   PubMed Web of Science ®Google Scholar
• Sun Q, Nan XY, Tian FM, et al. Raloxifene retards the progression of adjacent segmental intervertebral disc degeneration by inhibiting apoptosis of nucleus pulposus in ovariectomized rats. J. Orthop Surg Res. 2021;16(1):368. doi:10.1186/s13018-021-02504-4
   PubMed Web of Science ®Google Scholar
• Chiou WC, Hsu MS, Chen YT, et al. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. J Enzyme Inhib Med Chem. 2021;36(1):147–153. doi:10.1080/14756366.2020.1850710
   PubMed Web of Science ®Google Scholar
• Hong S, Chang J, Jeong K, et al. Raloxifene as a treatment option for viral infections. J Microbiol. 2021;59(2):124–131. doi:10.1007/s12275-021-0617-7
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3(1):1351–1371. doi:10.3390/cancers3011351
   PubMedGoogle Scholar
• Kollmannsberger C, Honecker F, Bokemeyer C. Pharmacotherapy of relapsed metastatic testicular cancer. Expert Opin Pharmacother. 2008;9(13):2259–2272. doi:10.1517/14656566.9.13.2259
   PubMed Web of Science ®Google Scholar
• Razzaque MS. Cisplatin nephropathy: is cytotoxicity avoidable? Nephrol Dial Transplant. 2007;22(8):2112–2116. doi:10.1093/ndt/gfm378
   PubMed Web of Science ®Google Scholar
• Safirstein R, Winston J, Goldstein M, et al. Cisplatin nephrotoxicity. Am J Kidney Dis. 1986;8(5):356–367. doi:10.1016/S0272-6386(86)80111-1
   PubMed Web of Science ®Google Scholar
• Filipski KK, Mathijssen RH, Mikkelsen TS, et al. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86(4):396–402. doi:10.1038/clpt.2009.139
   PubMed Web of Science ®Google Scholar
• Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014;2014:967826. doi:10.1155/2014/967826
   PubMed Web of Science ®Google Scholar
• Abd El-Rhman RH, El-Naga RN, Gad AM, et al. Dibenzazepine attenuates against cisplatin-induced nephrotoxicity in rats: involvement of NOTCH pathway. Front Pharmacol. 2020;11:567852. doi:10.3389/fphar.2020.567852
   PubMed Web of Science ®Google Scholar
• Ko JW, Shin NR, Jung TY, et al. Melatonin attenuates cisplatin-induced acute kidney injury in rats via induction of anti-aging protein, Klotho. Food Chem Toxicol. 2019;129:201–210. doi:10.1016/j.fct.2019.04.049
   PubMed Web of Science ®Google Scholar
• Kandemir FM, Yildirim S, Caglayan C, et al. Protective effects of zingerone on cisplatin-induced nephrotoxicity in female rats. Environ Sci Pollut Res Int. 2019;26(22):22562–22574. doi:10.1007/s11356-019-05505-3
   PubMed Web of Science ®Google Scholar
• Abdellatief SA, Galal AA, Farouk SM, et al. Ameliorative effect of parsley oil on cisplatin-induced hepato-cardiotoxicity: a biochemical, histopathological, and immunohistochemical study. Biomed Pharmacother. 2017;86:482–491. doi:10.1016/j.biopha.2016.12.038
   PubMed Web of Science ®Google Scholar
• Abdel-Daim MM, Abdel-Rahman HG, Dessouki AA, et al. Impact of garlic (Allium sativum) oil on cisplatin-induced hepatorenal biochemical and histopathological alterations in rats. Sci Total Environ. 2020;710:136338. doi:10.1016/j.scitotenv.2019.136338
   PubMed Web of Science ®Google Scholar
• Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol. 2009;61(3):223–242. doi:10.1016/j.etp.2008.09.003
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Pei G, Kim ST, et al. Substance P antagonism as a novel therapeutic option to enhance efficacy of cisplatin in triple negative breast cancer and protect PC12 cells against cisplatin-induced oxidative stress and apoptosis. Cancers. 2021;13(15):3871. doi:10.3390/cancers13153871
   PubMed Web of Science ®Google Scholar
• Sadzuka Y, Shoji T, Takino Y. Mechanism of the increase in lipid peroxide induced by cisplatin in the kidneys of rats. Toxicol Lett. 1992;62(2–3):293–300. doi:10.1016/0378-4274(92)90033-G
   PubMed Web of Science ®Google Scholar
• Zhang JG, Lindup WE. Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol. 1993;45(11):2215–2222. doi:10.1016/0006-2952(93)90192-Y
   PubMed Web of Science ®Google Scholar
• Capizzi RL. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin Oncol. 1999;26(2 Suppl 7):72–81.
   PubMed Web of Science ®Google Scholar
• Culy CR, Spencer CM. Amifostine. Drugs. 2001;61(5):641–684. doi:10.2165/00003495-200161050-00012
   PubMedGoogle Scholar
• Javaherforooshzadeh F, Shaker Z, Rashidi M, et al. The effect of N-acetyl cysteine injection on renal function after coronary artery bypass graft surgery: a randomized double blind clinical trial. J Cardiothorac Surg. 2021;16(1):161. doi:10.1186/s13019-021-01550-7
   PubMed Web of Science ®Google Scholar
• Mainra R, Gallo K, Moist L. Effect of N-acetylcysteine on renal function in patients with chronic kidney disease. Nephrology. 2007;12(5):510–513. doi:10.1111/j.1440-1797.2007.00833.x
   PubMed Web of Science ®Google Scholar
• Porfire AS, Leucuţa SE, Kiss B, et al. Investigation into the role of Cu/Zn-SOD delivery system on its antioxidant and antiinflammatory activity in rat model of peritonitis. Pharmacol Rep. 2014;66(4):670–676. doi:10.1016/j.pharep.2014.03.011
   PubMed Web of Science ®Google Scholar
• Jeeva JS, Sunitha J, Ananthalakshmi R, et al. Enzymatic antioxidants and its role in oral diseases. J Pharm Bioallied Sci. 2015;7(Suppl 2):S331–S333. doi:10.4103/0975-7406.163438
   PubMedGoogle Scholar
• Younus H. Therapeutic potentials of superoxide dismutase. Int J Health Sci. 2018;12(3):88–93.
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Siddhanti S, Ciaccia AV, et al. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6(3):212–224. doi:10.1093/humupd/6.3.212
   PubMed Web of Science ®Google Scholar
• Lu Y, Cohen F, Lakshmanan M. Characterization of hot flashes during raloxifene therapy: analyses of adverse event reports from an integrated placebo-controlled clinical trial database. Menopause. 1998;5(4):282. doi:10.1097/00042192-199805040-00136
   Google Scholar
• Shi W, Yan D, Zhao C, et al. Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista. Biochem Biophys Res Commun. 2017;491(1):159–165. doi:10.1016/j.bbrc.2017.07.067
   PubMed Web of Science ®Google Scholar
• Olivier S, Close P, Castermans E, et al. Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappa B inhibition and gene expression signature. Mol Pharmacol. 2006;69(5):1615–1623. doi:10.1124/mol.105.020479
   PubMed Web of Science ®Google Scholar
• Jang HS, Pearce M, O’Donnell EF, et al. Identification of a raloxifene analog that promotes AhR-mediated apoptosis in cancer cells. Biology. 2017;6(4):41. doi:10.3390/biology6040041
   PubMedGoogle Scholar